Cytori names Gregg Lapointe to board.
M2 EQUITYBITES-April 4, 2017-Cytori names Gregg Lapointe to board
(C)2017 M2 COMMUNICATIONS http://www.m2.com
Therapeutics company Cytori Therapeutics Inc (NasdaqCM:CYTX) reported on Monday the addition of Gregg Lapointe as an independent director to its board of directors with effect from 31 March 2017.
Currently, Lapointe is a co-founder and CEO of Cerium Pharmaceuticals; a member of the board of directors of SciClone Pharmaceuticals, Soligenix and Immunocellular Therapeutics; and a member of the board of trustees of the Keck Graduate Institute of Applied Life Sciences.
Previously, Lapointe was the CEO at Sigma-Tau Pharmaceuticals, held various roles at AstenJohnson, Medical Plastic Devices Inc and Ingram & Bell Meditron, senior manager at Zittrer Siblin Stein Levine, as well as a chartered accountant and audit manager at Price Waterhouse at the start of his career.
Earlier in his career, Lapointe was a board member and chair of the Rare Disease Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA) as well as a member of the board of directors of Questcor Pharmaceuticals and Raptor Pharmaceutical Corp.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Apr 4, 2017|
|Previous Article:||Five John Hancock closed-end funds announce distributions for April 2017.|
|Next Article:||Marina Biotech signs manufacturing agreement for IT-102 FDC bi-layer tablet.|